This company listing is no longer active
Protalix BioTherapeutics Bilan de santé
Santé financière contrôle des critères 0/6
Informations clés
-264.9%
Ratio d'endettement
US$28.19m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$22.18m |
| Fonds propres | -US$10.64m |
| Total du passif | US$66.43m |
| Total des actifs | US$55.79m |
Mises à jour récentes de la santé financière
Recent updates
Analyse de la situation financière
Passif à court terme: PLX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passif à long terme: PLX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: PLX has negative shareholder equity, which is a more serious situation than a high debt level.
Réduire la dette: PLX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: PLX has less than a year of cash runway based on its current free cash flow.
Prévisions de trésorerie: PLX has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.5% each year.